Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ABBOTT LABORATORIES T.ABT


Primary Symbol: ABT

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.


NYSE:ABT - Post by User

Bullboard Posts
Post by JSP127on May 05, 2009 7:07pm
699 Views
Post# 15969290

Striking comments in the recent report.

Striking comments in the recent report.
"Revenue was $38.9 million YTD, an increase of 46% from $26.6 million in the same period last year. Revenue in Q3-F2009 increased 35% to $13.7 million, compared to $10.1 million in Q3-F2008. Revenue is considered a lagging performance indicator as it is a function of deferred revenue as opposed to sales in the quarter. Substantially all of the revenue from Q3-F2009 Sales Contracts is included in deferred revenue on the balance sheet at March 31, 2009, which climbed to $97.3 million, compared to $87.8 million at June 30, 2008."


"Absolute is in a strong financial position, with no debt and the financial resources necessary to fund its operating and capital requirements and to execute on its growth strategies. Accordingly, the company launched a normal course issuer bid in November 2008 for the repurchase and retirement of up to 4.2 million of Absolute's shares. Under this bid, Absolute had repurchased 3.3 million shares for a total of $10.6 million. After the share repurchase, at March 31, 2009, Absolute's cash, cash equivalents and investments (including long term) were $67.2 million, compared to $64.0 million at June 30, 2008"
Bullboard Posts